A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Two-Period Crossover Study to Investigate the Safety of CAL-101 in Allergic Rhinitis Subjects and Effects on the Response to Environmental Chamber Allergen Challenge.

Trial Profile

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Two-Period Crossover Study to Investigate the Safety of CAL-101 in Allergic Rhinitis Subjects and Effects on the Response to Environmental Chamber Allergen Challenge.

Completed
Phase of Trial: Phase I

Latest Information Update: 23 Feb 2016

At a glance

  • Drugs Idelalisib (Primary)
  • Indications Grass pollen hypersensitivity; Seasonal allergic rhinitis
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Most Recent Events

    • 23 Feb 2016 Primary endpoint has been met (Mean change from baseline in average TNSS) as per the the results published in the Journal of Allergy and Clinical Immunology.
    • 23 Feb 2016 Results published in the Journal of Allergy and Clinical Immunology
    • 04 May 2011 Additional lead trial centre identified as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top